VolitionRx Limited (NYSE American: VNRX) has announced the publication of a peer-reviewed study in Critical Care Medicine demonstrating that its Nu.Q NETs H3.1 biomarker is an independent predictor of 28-day mortality and the need for renal replacement therapy in patients with sepsis and septic shock. The findings underscore the clinical utility of the biomarker for risk stratification and early intervention, potentially transforming sepsis management.
The study, which involved patients with sepsis and septic shock, found significantly higher Nu.Q NETs H3.1 levels in septic shock patients compared to those with sepsis alone. Moreover, the biomarker exhibited a dose-response relationship with acute kidney injury severity, suggesting that higher levels correlate with worse outcomes. An independent editorial accompanying the study examines H3.1 nucleosomes as a potential marker of NET-mediated organ injury, further validating the biological relevance of the biomarker.
Sepsis remains a leading cause of death worldwide, with timely intervention being critical. Current diagnostic tools often fall short in predicting disease trajectory. The Nu.Q NETs test, which measures circulating nucleosomes released during NETosis, offers a rapid and quantitative assessment that could help clinicians anticipate complications, guide treatment decisions, and monitor patients over time. VolitionRx believes this test could be applied across both acute and chronic conditions associated with NETosis, including sepsis and potentially cancer.
The company cites a total addressable market of $2.8 billion for this technology. The latest findings add to a growing body of evidence supporting its clinical utility. Dr Andrew Retter, Medical Consultant at Volition, commented: “Introducing Nu.Q NETs into hospitals, as a treatable, trackable trait, could lead to new ways of treating sepsis, improve patient survival and the quality of life of survivors.”
This publication not only strengthens VolitionRx's commercial positioning but also highlights the broader potential of nucleosome quantification in precision medicine. For a disease where every hour counts, having a biomarker that predicts outcomes could shift sepsis management from reactive to proactive, potentially saving lives and reducing healthcare costs. The company is actively engaging in commercial and licensing discussions, aiming to bring this test to clinical settings.
For more details on the study and VolitionRx's pipeline, visit https://ibn.fm/RErhc.
